PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-26.20%
Both yoy net incomes decline, with AXSM at -0.01%. Martin Whitman would view it as a broader sector or cyclical slump hitting profits.
3.65%
Less D&A growth vs. AXSM's 11.65%, reducing the hit to reported earnings. David Dodd would confirm that core assets remain sufficient.
No Data
No Data available this quarter, please select a different quarter.
-4.67%
Both cut yoy SBC, with AXSM at -17.27%. Martin Whitman would view it as an industry shift to reduce stock-based pay or a sign of reduced expansions.
-515.11%
Negative yoy working capital usage while AXSM is 5856.41%. Joel Greenblatt would see more free cash if revenue remains unaffected, giving a short-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
21.40%
Growth well above AXSM's 22.88%. Michael Burry would see a potential hidden liquidity or overhead issue overshadowing competitor's approach.
-12704.62%
Both negative yoy, with AXSM at -8.23%. Martin Whitman would suspect an overall environment of intangible cleanup or shifting revaluations for the niche.
-57.07%
Negative yoy CFO while AXSM is 22.89%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
-196.22%
Negative yoy CapEx while AXSM is 12.01%. Joel Greenblatt would see a near-term FCF boost unless competitor invests for long-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-196.22%
We reduce yoy invests while AXSM stands at 12.01%. Joel Greenblatt sees near-term liquidity advantage unless competitor’s expansions yield high returns.
No Data
No Data available this quarter, please select a different quarter.
100.00%
We slightly raise equity while AXSM is negative at -28.64%. John Neff sees competitor possibly preserving share count or buying back shares.
No Data
No Data available this quarter, please select a different quarter.